Phathom Pharmaceuticals, Inc. — Form 8-K
Filed October 29, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Phathom Pharmaceuticals reported Q3 2026 net revenues of $84.7 million (up 71% vs. Q3 2025, up 14% vs. Q2 2026), driven by continued VOQUEZNA commercialization reaching 2 million total prescriptions filled through October 16, 2026. The company achieved positive operating cash flow for the second consecutive quarter, generated non-GAAP adjusted net income of $3.0 million (vs. adjusted net loss of $11.2 million in Q3 2025), and maintained full-year 2026 guidance of $310–325 million net revenue. Cash position as of September 30, 2026 was $184.6 million, with the company facing litigation risk from BDR Pharmaceuticals challenging VOQUEZNA's 10-year NCE exclusivity (through May 3, 2032), though the company expects Q4 2026 topline results from its Phase 2 EoE trial and initiated a Phase 3 as-needed use study (pHalcon-NERD-302) with topline results expected Q1 2028.
Why this rating
Strong revenue growth (71% YoY) and return to profitability are meaningful for $555M-market-cap company; however, regulatory exclusivity litigation poses material downside risk to long-term value. Net event moderately positive.
See more from October 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.